首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1812042篇
  免费   134113篇
  国内免费   3001篇
耳鼻咽喉   26209篇
儿科学   55974篇
妇产科学   50205篇
基础医学   259243篇
口腔科学   52200篇
临床医学   160664篇
内科学   342800篇
皮肤病学   38878篇
神经病学   141714篇
特种医学   72415篇
外国民族医学   373篇
外科学   278938篇
综合类   43664篇
现状与发展   3篇
一般理论   528篇
预防医学   134728篇
眼科学   42542篇
药学   141572篇
  8篇
中国医学   4078篇
肿瘤学   102420篇
  2018年   17530篇
  2016年   15629篇
  2015年   17801篇
  2014年   24885篇
  2013年   36973篇
  2012年   50237篇
  2011年   52991篇
  2010年   31038篇
  2009年   29090篇
  2008年   49394篇
  2007年   53223篇
  2006年   53678篇
  2005年   51843篇
  2004年   50214篇
  2003年   48197篇
  2002年   46589篇
  2001年   87217篇
  2000年   89348篇
  1999年   75049篇
  1998年   20238篇
  1997年   18184篇
  1996年   18118篇
  1995年   17057篇
  1994年   15875篇
  1993年   15024篇
  1992年   59592篇
  1991年   57789篇
  1990年   56799篇
  1989年   54842篇
  1988年   50370篇
  1987年   49327篇
  1986年   46656篇
  1985年   44501篇
  1984年   33195篇
  1983年   28316篇
  1982年   16682篇
  1981年   14896篇
  1979年   31695篇
  1978年   22098篇
  1977年   19262篇
  1976年   17148篇
  1975年   19111篇
  1974年   22992篇
  1973年   22108篇
  1972年   21111篇
  1971年   19731篇
  1970年   18502篇
  1969年   17973篇
  1968年   16085篇
  1967年   14613篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional...  相似文献   
3.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
4.

Physical activity brings significant health benefits to middle-aged adults, although the research to date has been focused on late adulthood. This study aims to examine how ageing affects the self-reported and accelerometer-derived measures of physical activity levels in middle-aged adults. We employed the data recorded in the UK Biobank and analysed the physical activity levels of 2,998 participants (1381 men and 1617 women), based on self-completion questionnaire and accelerometry measurement of physical activity. We also assessed the musculoskeletal health of the participants using the dual-energy X-ray absorptiometry (DXA) measurements provided by the UK Biobank. Participants were categorised into three groups according to their age: group I younger middle-aged (40 to 49 years), group II older middle-aged (50 to 59 years), and group III oldest middle-aged (60 to 69 years). Self-reported physical activity level increased with age and was the highest in group III, followed by group II and I (P?<?0.05). On the contrary, physical activity measured by accelerometry decreased significantly with age from group I to III (P?<?0.05), and the same pertained to the measurements of musculoskeletal health (P?<?0.05). It was also shown that middle-aged adults mostly engaged in low and moderate intensity activities. The opposing trends of the self-reported and measured physical activity levels may suggest that middle-aged adults over-report their activity level as they age. They should be aware of the difference between their perceived and actual physical activity levels, and objective measures would be useful to prevent the decline in musculoskeletal health.

  相似文献   
5.
6.
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing.  相似文献   
7.
8.
9.
10.
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号